PharMerica Company Profile (NYSE:PMC)

About PharMerica (NYSE:PMC)

PharMerica logoPharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Stores
  • Sub-Industry: Health Care Distributors
  • Symbol: NYSE:PMC
  • CUSIP: 71714F10
  • Web:
  • Market Cap: $782.01 million
  • Outstanding Shares: 31,094,000
Average Prices:
  • 50 Day Moving Avg: $23.97
  • 200 Day Moving Avg: $24.42
  • 52 Week Range: $19.20 - $28.72
  • Trailing P/E Ratio: 37.54
  • Foreward P/E Ratio: 11.59
  • P/E Growth: 1.37
Sales & Book Value:
  • Annual Revenue: $2.13 billion
  • Price / Sales: 0.37
  • Book Value: $17.70 per share
  • Price / Book: 1.42
  • EBIDTA: $130.2 million
  • Net Margins: 1.64%
  • Return on Equity: 10.40%
  • Return on Assets: 4.68%
  • Debt-to-Equity Ratio: 0.71%
  • Current Ratio: 3.10%
  • Quick Ratio: 2.25%
  • Average Volume: 198,823 shs.
  • Beta: 1.1
  • Short Ratio: 4.22

Frequently Asked Questions for PharMerica (NYSE:PMC)

What is PharMerica's stock symbol?

PharMerica trades on the New York Stock Exchange (NYSE) under the ticker symbol "PMC."

How were PharMerica's earnings last quarter?

PharMerica Co. (NYSE:PMC) announced its quarterly earnings data on Wednesday, May, 10th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.02. The business earned $566.80 million during the quarter, compared to analysts' expectations of $536.85 million. PharMerica had a return on equity of 10.40% and a net margin of 1.64%. The firm's quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.45 earnings per share. View PharMerica's Earnings History.

What guidance has PharMerica issued on next quarter's earnings?

PharMerica updated its FY17 earnings guidance on Wednesday, May, 10th. The company provided EPS guidance of $1.75-1.95 for the period, compared to the Thomson Reuters consensus estimate of $1.89. The company issued revenue guidance of $2.3-2.4 billion, compared to the consensus revenue estimate of $2.35 billion.

Where is PharMerica's stock going? Where will PharMerica's stock price be in 2017?

1 brokers have issued 12 month price targets for PharMerica's shares. Their predictions range from $32.00 to $32.00. On average, they expect PharMerica's stock price to reach $32.00 in the next twelve months. View Analyst Ratings for PharMerica.

Who are some of PharMerica's key competitors?

Who owns PharMerica stock?

PharMerica's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.91%), Dimensional Fund Advisors LP (8.46%), FMR LLC (6.46%), Vanguard Group Inc. (5.08%), Boston Partners (4.04%) and Victory Capital Management Inc. (3.00%). Company insiders that own PharMerica stock include Gregory S Weishar, Mark Lindemoen and Robert A Mckay. View Institutional Ownership Trends for PharMerica.

Who sold PharMerica stock? Who is selling PharMerica stock?

PharMerica's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., FMR LLC, Teachers Advisors LLC, Ameriprise Financial Inc., Bank of New York Mellon Corp, Systematic Financial Management LP, Victory Capital Management Inc. and Boston Partners. View Insider Buying and Selling for PharMerica.

Who bought PharMerica stock? Who is buying PharMerica stock?

PharMerica's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Sessa Capital IM L.P., Citadel Advisors LLC, Bank of America Corp DE, LSV Asset Management, First Trust Advisors LP, State Street Corp and Morgan Stanley. View Insider Buying and Selling for PharMerica.

How do I buy PharMerica stock?

Shares of PharMerica can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PharMerica stock cost?

One share of PharMerica stock can currently be purchased for approximately $25.15.

Analyst Ratings

Consensus Ratings for PharMerica (NYSE:PMC) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.00 (27.24% upside)

Analysts' Ratings History for PharMerica (NYSE:PMC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/7/2016Bank of America CorpInitiated CoverageBuy$32.00N/AView Rating Details
5/10/2016Barrington ResearchReiterated RatingOutperform$30.00 -> $34.00N/AView Rating Details
3/15/2016Credit Suisse Group AGInitiated CoverageOutperform$30.00N/AView Rating Details
2/29/2016KeyCorpLower Price TargetOverweight$39.00 -> $32.00N/AView Rating Details
2/29/2016Barclays PLCLower Price TargetUnderweight$27.00 -> $22.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuy$39.00 -> $41.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for PharMerica (NYSE:PMC)
Earnings by Quarter for PharMerica (NYSE:PMC)
Earnings History by Quarter for PharMerica (NYSE:PMC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017$0.40$0.42$536.85 million$566.80 millionViewN/AView Earnings Details
2/24/2017Q416$0.51$0.58$525.22 million$534.40 millionViewListenView Earnings Details
11/9/2016Q316$0.51$0.44$530.01 million$512.60 millionViewListenView Earnings Details
8/9/2016Q216$0.47$0.47$508.31 million$519.60 millionViewListenView Earnings Details
5/6/2016Q116$0.43$0.45$509.45 million$524.50 millionViewListenView Earnings Details
2/26/2016Q415$0.41$0.45$506.40 million$520.60 millionViewListenView Earnings Details
11/6/2015Q315$0.36$0.39$480.35 million$498.80 millionViewListenView Earnings Details
8/7/2015Q215$0.33$0.37$491.66 million$497.50 millionViewListenView Earnings Details
5/7/2015Q115$0.43$0.48$500.95 million$511.60 millionViewListenView Earnings Details
3/2/2015Q414$0.43$0.45$491.99 million$523.50 millionViewListenView Earnings Details
11/6/2014Q314$0.40$0.45$439.63 million$470.20 millionViewListenView Earnings Details
8/5/2014Q214$0.36$0.40$432.70 million$448.60 millionViewListenView Earnings Details
5/1/2014Q114$0.33$0.37$417.76 million$452.20 millionViewListenView Earnings Details
2/28/2014Q413$0.38$0.44$421.16 million$433.20 millionViewListenView Earnings Details
11/5/2013Q313$0.32$0.49$398.02 million$442.00 millionViewListenView Earnings Details
8/2/2013Q2 2013$0.34$0.44$414.15 million$458.50 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.34$0.46$435.10 million$439.80 millionViewListenView Earnings Details
2/7/2013Q4 2012$0.29$0.12$432.43 million$433.20 millionViewListenView Earnings Details
11/1/2012Q312$0.30$0.33$446.36 million$442.00 millionViewN/AView Earnings Details
8/2/2012$0.30$0.32ViewN/AView Earnings Details
5/2/2012$0.27$0.30ViewN/AView Earnings Details
2/9/2012$0.21$0.27ViewN/AView Earnings Details
11/3/2011$0.20$0.31ViewN/AView Earnings Details
8/4/2011$0.20$0.32ViewN/AView Earnings Details
5/5/2011$0.20$0.21ViewN/AView Earnings Details
2/24/2011$0.17$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PharMerica (NYSE:PMC)
2017 EPS Consensus Estimate: $1.88
2018 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.40$0.40$0.40
Q2 20172$0.46$0.47$0.47
Q3 20172$0.48$0.49$0.49
Q4 20172$0.53$0.53$0.53
Q1 20181$0.48$0.48$0.48
Q2 20181$0.52$0.52$0.52
Q3 20181$0.55$0.55$0.55
Q4 20181$0.57$0.57$0.57
(Data provided by Zacks Investment Research)


Dividend History for PharMerica (NYSE:PMC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for PharMerica (NYSE:PMC)
Insider Ownership Percentage: 5.04%
Institutional Ownership Percentage: 97.15%
Insider Trades by Quarter for PharMerica (NYSE:PMC)
Institutional Ownership by Quarter for PharMerica (NYSE:PMC)
Insider Trades by Quarter for PharMerica (NYSE:PMC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2015Robert A MckaySVPSell2,993$34.42$103,019.06View SEC Filing  
11/11/2015Mark LindemoenSVPSell3,790$34.71$131,550.90View SEC Filing  
6/16/2015Robert A MckaySVPSell7,000$32.75$229,250.00View SEC Filing  
6/3/2015Gregory S WeisharCEOSell104,150$32.63$3,398,414.50View SEC Filing  
6/1/2015Mark LindemoenSVPSell4,500$33.27$149,715.00View SEC Filing  
3/12/2015Berard TomassettiCAOSell3,344$26.44$88,415.36View SEC Filing  
3/12/2015Thomas A CanerisSVPSell7,495$26.52$198,767.40View SEC Filing  
3/6/2015Robert A MckaySVPSell20,000$26.74$534,800.00View SEC Filing  
8/8/2014Robert A OakleyDirectorSell8,399$26.55$222,993.45View SEC Filing  
5/13/2014Thomas CanerisSVPSell12,192$28.60$348,691.20View SEC Filing  
3/14/2014Gregory WeisharCEOSell60,000$26.27$1,576,200.00View SEC Filing  
3/13/2014Robert MckaySVPSell18,646$26.08$486,287.68View SEC Filing  
3/12/2014Berard TomassettiCAOSell3,812$25.22$96,138.64View SEC Filing  
3/6/2014Thomas CanerisSVPSell14,357$25.60$367,539.20View SEC Filing  
11/22/2013Thomas GerrityDirectorSell3,271$20.56$67,251.76View SEC Filing  
11/15/2013Berard TomassettiCAOSell4,097$20.55$84,193.35View SEC Filing  
5/30/2013Berard TomassettiCAOSell9,724$15.68$152,472.32View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for PharMerica (NYSE:PMC)
Latest Headlines for PharMerica (NYSE:PMC)
DateHeadline logoKeyCorp Analysts Increase Earnings Estimates for PharMerica Co. (PMC) - May 17 at 8:44 AM logoEdited Transcript of PMC earnings conference call or presentation 10-May-17 2:00pm GMT - May 16 at 9:48 AM logoPharMerica Co. (PMC) Upgraded to "Hold" by Zacks Investment Research - May 16 at 8:10 AM logoPharMerica Co. Expected to Earn Q2 2017 Earnings of $0.46 Per Share (PMC) - May 16 at 7:52 AM logoQ2 2017 Earnings Estimate for PharMerica Co. Issued By Barrington Research (PMC) - May 15 at 7:30 AM logo$573.5 Million in Sales Expected for PharMerica Co. (PMC) This Quarter - May 13 at 7:38 AM logoResearch Analysts Issue Forecasts for PharMerica Co.'s Q4 2017 Earnings (PMC) - May 12 at 3:24 PM logo Brokerages Anticipate PharMerica Co. (PMC) Will Post Earnings of $0.46 Per Share - May 11 at 8:20 PM logoPharMerica beats 1Q estimates, reveals acquisition - May 10 at 7:29 PM logoPharMerica Co. (PMC) Announces Quarterly Earnings Results - May 10 at 4:16 PM logoPharMerica Reports First Quarter 2017 Results - May 10 at 11:36 AM logoPharMerica beats 1Q profit forecasts - May 10 at 11:36 AM logoPharMerica Co. (PMC) Releases FY17 Earnings Guidance - May 10 at 9:00 AM logoPharMerica (PMC) Earns Daily News Impact Score of 0.16 - May 4 at 12:06 PM logoPharmerica reveals how much executives made in 2016 - May 2 at 5:04 PM logoPositive News Coverage Likely to Affect PharMerica (PMC) Stock Price - April 29 at 10:22 PM logoPharMerica Corp. – Value Analysis (NYSE:PMC) : April 27, 2017 - April 27 at 7:43 PM logoPharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : April 26, 2017 - April 26 at 6:01 PM logo$536.5 Million in Sales Expected for PharMerica Co. (PMC) This Quarter - April 23 at 10:19 AM logoPharMerica Corporation Announces First Quarter 2017 Earnings Call and Webcast - April 19 at 7:16 PM logoPharMerica (PMC) Earns Daily Media Impact Rating of 0.69 - April 16 at 7:52 AM logoPharMerica Announces Date of 2017 Annual Meeting of Shareholders - April 7 at 7:37 PM logoPHARMERICA CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statem - March 30 at 7:31 PM logoPharMerica Acquires CareMed Specialty Pharmacy - March 16 at 7:59 PM logoPharMerica Co. (PMC) Cut to Sell at Zacks Investment Research - March 12 at 6:21 PM logoPharMerica (PMC): Moving Average Crossover Alert - March 8 at 4:02 PM logoPHARMERICA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - February 27 at 9:48 AM logoPharMerica Corp Earnings Call scheduled for 10:00 am ET today - February 25 at 1:28 AM logoEdited Transcript of PMC earnings conference call or presentation 24-Feb-17 3:00pm GMT - February 25 at 1:28 AM logoPharMerica beats 4Q profit forecasts - February 24 at 8:27 PM logoPharMerica's (PMC) CEO Greg Weishar on Q4 2016 Results - Earnings Call Transcript - February 24 at 8:27 PM logoPharmerica increases goal for merger revenue in Q4 earnings call - February 24 at 8:27 PM logoQ4 2016 PharMerica Corp Earnings Release - Before Market Open - February 24 at 8:28 AM logoPharMerica Reports Fourth Quarter and Full Year 2016 Results - February 24 at 8:28 AM logoPharMerica Corporation Announces Fourth Quarter and Year End 2016 Earnings Call and Webcast - February 3 at 8:08 PM logoPharMerica hires a new top executive - February 1 at 9:56 PM logoPharmerica (PMC) Names Robert Dries as CFO - February 1 at 9:56 PM logoPharMerica Appoints Robert E. Dries as Executive Vice President and Chief Financial Officer - February 1 at 9:56 PM logo9:01 am PharMerica appoints Robert E. Dries as Chief Financial Officer effective January 31 - February 1 at 9:56 PM logoPharMerica Announces Expansion of Existing Credit Facility, Increasing Borrowing Capacity by $150 Million - December 15 at 8:31 PM logo4:20 pm PharMerica amends its existing credit agreement with Bank of America to increase the Co's borrowing capacity by approx. $150 million; - December 15 at 8:31 PM logoPHARMERICA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S - December 15 at 8:31 PM logoPHARMERICA CORP Financials - November 17 at 6:35 PM



PharMerica (PMC) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff